ALNY - Alnylam Pharmaceuticals, Inc.
| Previous Close | 70.03 |
| Open | 70.31 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 69.84 - 72.24 |
| 52 Week Range | 60.27 - 124.22 |
| Volume | 595,518 |
| Avg. Volume | 970,087 |
| Market Cap | 7.617B |
| Beta (3Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.87 |
| Earnings Date | Jul 31, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 121.56 |
- Zacks•15 hours ago
Regeneron (REGN) Presents Positive Data on Lymphoma Candidate
Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.
- Business Wire•18 hours ago
Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of adults and children with primary hyperoxaluria type 1 (PH1). Alnylam is on track to report topline results from ILLUMINATE-A expected in late 2019 and, if positive, to submit filings for global regulatory approvals starting in early 2020. “We are pleased to have reached two important milestones for our PH1 program, timely completion of enrollment in ILLUMINATE-A – our Phase 3 pivotal study in adults and children – and successful completion of our Phase 1/2 study with positive final results,” said Pritesh J. Gandhi, PharmD, Vice President and General Manager, Lumasiran program at Alnylam.
- Simply Wall St.•4 days ago
Why Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is A Financially Healthy Company
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Alnylam...
- American City Business Journals•5 days ago
Boston-area biopharm firm has big plans in Philadelphia
Alnylam Pharmaceuticals, a Massachusetts biopharmaceutical company that specializes in RNA interference therapeutics, is expanding its operations into Philadelphia. “We have a small team there now,” said John Maraganore, the CEO of Cambridge, Mass.-based Alnylam. “There’s a lot of competition for talent up here and there is lot of [life sciences industry] talent in the tri-state area there around Philadelphia.
- Markit•5 days ago
See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.56 billion over the last one-month into ETFs that hold ALNY are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•5 days ago
Alnylam to Report New Clinical Results for ONPATTRO® (patisiran) at Peripheral Nerve Society (PNS) Annual Meeting and the 5th Congress of the European Academy of Neurology (EAN)
– Data from Ongoing Open-Label Extension Study Highlight Durable Halting or Reversal of Neuropathy Disease Progression Relative to Baseline and Consistent Safety Profile of ONPATTR
- Zacks•12 days ago
Alnylam Completes Rolling NDA Submission to FDA for Givosiran
Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.
- Business Wire•13 days ago
Alnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP).
- Zacks•15 days ago
Alnylam Initiates Phase I Study on Hypertension Candidate
Alnylam (ALNY) initiates phase I study on ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen for the treatment of hypertension in high unmet need populations.
- Zacks•18 days ago
Why Is Alnylam (ALNY) Down 16.8% Since Last Earnings Report?
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•18 days ago
Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the first patient has been dosed in the Company’s Phase 1 study of ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension in high unmet need populations, including patients with resistant or refractory hypertension, chronic kidney disease or heart failure. The Company expects to report initial results in late 2019.
- Business Wire•19 days ago
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
- Zacks•20 days ago
BioMarin Announces Data on Hemophilia Candidate, Shares Fall
BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.
- Business Wire•20 days ago
Alnylam Announces New Leadership Appointments
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today the appointment of Kelley Boucher as the Company’s Senior Vice President (SVP), Chief Human Resources Officer (CHRO) and the promotion of Kevin Fitzgerald, Ph.D., as SVP, Chief Scientific Officer (CSO).
- InvestorPlace•29 days ago
Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock
After upgrading Pfizer (NYSE:PFE) to "Outperform" in January and raising its price target on Pfizer stock to $48 in May, one would think there's nothing else Credit Suisse could so to bolster its bullish case, but there is.Source: Kojach Via FlickrFollowing a meeting with the pharmaceutical giant's top brass just a few days ago, on Thursday, Credit Suisse labeled PFE stock a "top pick." It was apparently one heck of a meeting.The specifics prompting the accolade weren't made crystal clear, though Credit Suisse did note that the company's prospects for new products was compelling. Translation: Whatever stoked Credit Suisse's fires is likely to be in the company's late-stage pipeline, which is admittedly more exciting than it has been in a long while.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 High-Yield REITs to Buy (Even When the Market Tanks) A Brief Look at PfizerIt's not a story that needs a great deal of retelling. It was an unstoppable powerhouse when it had full patent protection of its erectile dysfunction drug Viagra and faced little competition. But, seeing the writing on the wall, the drugmaker allowed Teva Pharmaceutical Industries (NYSE:TEVA) to begin selling a generic version of the drug in 2017. In the meantime, consumer interest in ED drugs has broadly waned.Pfizer is about to lose ground with blockbuster neuropathic pain drug Lyrica too, which lost patent protection last year, threatening to quickly cut its $5 billion in annual sales in half once generic alternatives become available.It's the same story that plays out over and over within the pharmaceutical industry; these organizations must constantly replenish their portfolios with patent-protected drugs, or risk losing ground.It's something Pfizer hasn't done especially well in recent years.Although Pfizer stock has made reliable if choppy progress since turning around with all other stocks in 2009, revenue growth hasn't been overwhelming. The $53.9 billion in sales generated over the course of the past four reported quarters was not remarkable better than the $52.7 billion figure from a year earlier."Pfizer has been working through a dark period with extensive patent expirations," Credit Suisse analyst Vamil Divan said in late January. "That period is now nearing an end." Solid PipelineWhat Pfizer told Credit Suisse at the meeting remains veiled, though when Divan upgraded Pfizer stock early this year he explicitly noted opportunities for several cancer and autoimmune disease drugs along with vaccinations.Two of the drugs Divan had in mind are Vyndaqel and Vyndamax (though they're actually different doses of the same molecule), which combats the buildup for amyloid in the heart.Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) already make similar rival drugs, but their versions are considerably more expensive. Divan foresees peak sales of $2 billion for Vyndaqel, but is willing to entertain a number "significantly larger than that if Pfizer is able to commercialize it successfully."Pfizer has also partnered with Eli Lilly (NYSE:LLY) on the development of a non-opioid arthritis treatment called tanezumab, another one of the 15 game-changing drugs Pfizer believes could be brought to the market within the next five years.Some analysts are looking for modest peak sales of around $500 million, although Cantor Fitzgerald analyst Louise Chen thinks tanezumab could prove to a multi-billion dollar opportunity to replace a significant piece of the existing opioid market.In the meantime, Pfizer aims to widen the uses of already-marketable drugs like Ibrance, Eliquis, and Xeljanz.Ibrance has already become something of a wonder drug. Already approved as a therapy for multiple forms of breast cancer and generating revenue of $4.1 billion last year, expanded labeling could translate into peak annualized revenue of $8 billion before the treatment hits its ceiling.Eliquis (or Apixaban) for blood clots, co-marketed with Bristol-Myers Squibb (NYSE:BMY), and arthritis/ulcerative colitis therapy Xeljanz generated nearly $3.5 billion and more than $1.7 billion worth of revenue for Pfizer last year, respectively, yet both are also in trials for new uses after having proven they're safe and effective.All told, Pfizer's got 23 phase 3 trials underway right now. All of them look promising; most of them appear to have blockbuster potential. Looking Ahead for Pfizer StockIt was self-serving to be sure when CEO Albert Bourla proclaimed in January that Pfizer is sitting on its "greatest pipeline ever."But that doesn't mean he's wrong.Granted, the deterioration of Pfizer stock since December's peak (PFE stock been performing completely contrary to the market for months) says investors don't exactly believe Bourla. The crowd has understandably become a "show me first" mob, willing to wait on the sidelines for proof that the pipeline can do all the company suggests it can do.Credit Suisse's Divan may have the right idea though. The time to step into a great prospect is when its stock is down because the majority of investors aren't convinced and analysts are collectively lukewarm because they're unable to see more than a few months down the road.That's certainly Pfizer stock right now.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 High-Yield REITs to Buy (Even When the Market Tanks) * 5 Great Blue-Chip Stocks to Buy Today * 7 Tech Stocks to Buy That Are Also Perfect for Retirement Compare Brokers The post Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock appeared first on InvestorPlace.
- Business Wire•last month
Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Merrill Lynch Health Care Conference 2019 on Thursday, May 16, 2019 at 9:20 am PT (12:20 pm ET) at the Encore Hotel in Las Vegas, Nevada.
- Zacks•last month
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
- Motley Fool•last month
Can Pfizer Leap Over the Competition With This Potential Blockbuster?
It's been nearly seven years since the FDA refused to approve tafamidis's first new drug application, and the field is a lot more crowded now.
- Investor's Business Daily•last month
How Dow Jones' Pfizer Could Take On New Drugs From 2 Biotech Stocks
Dow Jones component Pfizer gained approval Monday for a drug that treats a rare heart disease — potentially rivaling new drugs from Alnylam Pharmaceuticals and Ionis Pharmaceuticals.
- Motley Fool•last month
Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come
Additional drug approvals and launches are on the way.
